STAT+: Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds
Start here
Gilead's oral drug emvistegrast achieved a 23% placebo-adjusted clinical remission rate in a Phase 2 trial in moderate to severe ulcerative colitis, a statistically significant difference. The results with the 200 mg daily dose over 12 weeks exceeded Wall Street analyst expectations. Swati Tole, Gilead's senior vice president of clinical development for inflammatory diseases, said emvistegrast has the potential to become a best-in-class oral therapy for this indication.
Excerpted from STAT
Coverage timeline
Follow the coverage to see the different angles.
- STATPickSTAT+: Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds
Gilead's oral drug emvistegrast achieved a 23% placebo-adjusted clinical remission rate in a Phase 2 trial in moderate to severe ulcerative colitis, a statistically significant difference. The results with the 200 mg daily dose over 12 weeks exceeded Wall Street analyst expectations. Swati Tole, Gilead's senior vice president of clinical development for inflammatory diseases, said emvistegrast has the potential to become a best-in-class oral therapy for this indication.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 19 17:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.